Anthropic has published research showing its Claude models can run protein-design campaigns largely on their own, achieving success rates that beat the typical industry benchmark and opening a new chapter for general AI models in drug discovery.
The company tested its Mythos Preview and Opus 4.8 models, letting them operate autonomously with a single expert-written prompt, internet access, and laboratory tools. The models produced working molecules on 14 of 15 targets, with success rates between 22% and 35% on molecules that actually bound their intended target. The industry norm sits at roughly 10% to 15%.
Anthropic did not carry out the physical lab work itself. Twist Bioscience and Adaptyv Bio created the candidate molecules in their own laboratories and ran the measurements independently, lending external credibility to the results.
In a separate demonstration, Opus 5 opened raw instrument files without using specialised lab software. It measured a sample at 96.4% purity in 19 minutes, while the laboratory’s own report on the same sample took four days to produce.
This result matters because CEO Dario Amodei said on X last week that Anthropic hoped for early glimmers in biology and medicine in the coming months. That timeline proved conservative. While artificial intelligence has been used in protein design before, the distinction here is that a general-purpose model achieved these results while directing the campaign itself, not simply assisting a human researcher through a single step.
The implications for pharmaceutical research are significant. A general model that can plan and execute a design campaign reduces the need for highly specialised narrow systems at the early discovery stage. If the success rates hold at scale, the cost and time required to move from target identification to candidate molecules could shrink noticeably.
For now the work remains at the proof-of-concept stage, and real-world drug development involves many more stages after candidate identification. Still, the speed at which Claude moved from promise to measurable laboratory outcome suggests the gap between AI capability and biological application is narrowing faster than many expected.
